
Join our team and drive the future of programmable eRNATM therapeutics and In Vivo CAR-T therapies- where artificial intelligence, targeted delivery systems and next-generation immunotherapy converge to redefine what’s possible for patients. As a key member of the Sail Biomedicines Computational Biology team, the Senior Scientist I will operate at the interface of platform and program, applying data-driven approaches to champion broad platform efforts and hands-on analysis of preclinical datasets to transform the treatment landscape for autoimmune diseases, and beyond.
The ideal candidate brings a strong foundation in computational biology and a record of independently developing, implementing, and critically evaluating computational methods for biological research. They should be comfortable reasoning through methodological assumptions, limitations, and biological implications of an analysis, from raw measurements through interpretation.
The role will directly support In Vivo CAR-T immunology programs and platform development, with opportunities to contribute to building capabilities spanning molecular and systems modeling, computational protein design, and AI-based therapeutic engineering.
Sail Biomedicines is building a new class of fully programmable medicines by integrating circular RNA (eRNA™), targeted nanoparticle delivery, and advanced computational approaches. Our platform enables the systematic design and optimization of therapies, unlocking new possibilities across immunology and beyond.
Salary Range: $130,000 - $170,000
Sail Biomedicines is an Equal Opportunity Employer. Sail does not discriminate based on race, religion, color, sex, gender identity, sexual orientation, age, national origin, veteran status, or any other status protected under federal, state, or local law.

Sail Biomedicines is creating a new class of RNA medicines designed to instruct therapeutic activity directly inside a patient’s body and within selected cells. Sail’s platform integrates Endless RNA™ (eRNA™), targeted nanoparticle delivery, and AI-enabled design to develop medicines with optimized therapeutic performance. The company is focused on applying its platform to In Vivo CAR-T medicines for immune-mediated diseases, with the goal of bringing the curative potential of CAR-T cell therapy to substantially more patients. Sail was founded by Flagship Pioneering and is headquartered in Cambridge, Massachusetts.